Description

SILYDOC 140MG (Silymarin + Silybin)

Indications

SILYDOC 140MG is a hepatoprotective formulation containing the flavonolignans
ilymarin and silybin, derived from the milk thistle plant (Silybum marianum).
It is used as an adjunctive therapy in patients with various liver disorders,
including fatty liver disease (alcoholic and non-alcoholic), toxic or drug-induced
liver injury, chronic hepatitis, and as supportive care in chronic liver disease
and cirrhosis. The product is intended to help support liver function, protect
hepatocytes from oxidative damage, and promote recovery in conditions characterized
by hepatic stress.

Mechanism of Action

Silymarin is a complex of flavonolignans, of which silybin is the major and most
active component. The hepatoprotective effects of SILYDOC 140MG are mediated through:

• Antioxidant action: Silymarin and silybin scavenge reactive oxygen species (ROS) and increase intracellular glutathione levels, thereby reducing lipid peroxidation in hepatocyte membranes.
• Membrane stabilization: By interacting with cell membranes, these compounds reduce the uptake of hepatotoxic substances and help maintain membrane integrity.
• Stimulation of protein synthesis: Silymarin can activate RNA polymerase I in the nucleus, leading to increased ribosomal protein synthesis and promoting regeneration of hepatocytes.
• Anti-inflammatory effects: Modulation of inflammatory pathways, including inhibition of NF-κB activation, contributes to reduced hepatic inflammation.
• Antifibrotic properties: Experimental data suggest an inhibitory effect on stellate cell activation and collagen deposition, which may help slow the progression of fibrosis.

Pharmacological Properties

After oral administration, silymarin is absorbed in the gastrointestinal tract and
undergoes extensive hepatic metabolism, primarily via conjugation. Silybin is the
most pharmacologically active constituent and exhibits a high affinity for liver tissue.
The bioavailability of silymarin is moderate and can be influenced by formulation and
food intake. Peak plasma levels are typically achieved within 2–4 hours after dosing.
Excretion occurs predominantly via bile in the form of conjugated metabolites; a smaller
fraction is eliminated in the urine.

SILYDOC 140MG is designed to deliver a standardized amount of silymarin and silybin to
ensure consistent hepatoprotective activity. Long-term administration is generally
required in chronic liver disorders to obtain sustained benefit.

Contraindications

SILYDOC 140MG is contraindicated in:

• Patients with known hypersensitivity or allergy to silymarin, silybin, milk thistle, or any excipients in the formulation.
• Individuals with a history of severe hypersensitivity reactions to herbal hepatoprotective products containing milk thistle.

Use in pregnancy and lactation should be based on a careful assessment of benefit versus
risk by the treating physician, as clinical data in these populations are limited.

Side Effects

SILYDOC 140MG is generally well tolerated when used at recommended doses. Reported side
effects, usually mild and transient, may include:

• Gastrointestinal symptoms such as nausea, abdominal discomfort, bloating, or diarrhea.
• Mild headache or dizziness in some individuals.
• Rare allergic reactions, including skin rash, pruritus, or urticaria, particularly in patients with known plant allergies.

If any severe or unusual symptoms occur (e.g. difficulty breathing, facial swelling,
generalized rash), use should be discontinued immediately and medical attention sought.

Dosage and Administration

The exact dosage regimen of SILYDOC 140MG should be determined by a healthcare
professional based on the underlying liver condition, severity of disease, concomitant
medications, and patient-specific factors.

• SILYDOC 140MG is typically administered orally with a glass of water.
• Taking the dose with food may improve gastrointestinal tolerability.
• The duration of therapy is often prolonged in chronic liver disorders and should follow medical advice.

Patients should be advised not to modify the dose or discontinue therapy
without consulting their physician, even if symptoms improve.

Interactions

Silymarin and silybin may interact with other medications through modulation of hepatic
drug-metabolizing enzymes and transporters. Potential interactions include:

• Drugs metabolized by CYP450 enzymes: In vitro data suggest that silymarin may affect certain cytochrome P450 isoenzymes; caution is advised when co-administered with drugs that have a narrow therapeutic index (e.g. some anticoagulants, antiepileptics, or immunosuppressants).
• Hepatotoxic drugs: In patients receiving potentially hepatotoxic agents (e.g. some chemotherapeutics, high-dose paracetamol), SILYDOC 140MG is often used as supportive therapy; close monitoring of liver function is recommended.

Patients should inform their healthcare provider of all prescription drugs, over-the-counter
medications, supplements, and herbal products they are using to avoid clinically relevant
interactions.

Precautions

• Use with caution in patients with severe hepatic impairment; although the product is hepatoprotective, dosage and monitoring should be individualized.
• In patients with a history of hormone-sensitive conditions, theoretical estrogenic effects of some plant constituents should be taken into account, although clinical relevance is uncertain.
• Regular monitoring of liver function tests (LFTs) may be appropriate in patients on long-term therapy or in those with advanced liver disease.
• Patients with known allergy to members of the Asteraceae/Compositae (daisy) family should use with caution.

Clinical Studies

Clinical and experimental studies on silymarin-containing preparations have demonstrated
beneficial effects on biochemical markers of liver function, oxidative stress, and
histological parameters in various liver disorders, including alcoholic liver disease,
non-alcoholic fatty liver disease (NAFLD), and chronic hepatitis. Improvements in serum
transaminases, bilirubin levels, and subjective symptoms (fatigue, abdominal discomfort)
have been reported in many trials.

While silymarin and silybin are widely used as hepatoprotective agents, the degree of
benefit may vary among individuals, and therapy is typically adjunctive to standard
medical and lifestyle measures (e.g. alcohol cessation, weight management, and control
of metabolic risk factors).

Conclusion

SILYDOC 140MG (Silymarin + Silybin) is a standardized hepatoprotective product designed
to support liver function and protect hepatocytes from oxidative and toxic injury. Its
antioxidant, membrane-stabilizing, and regenerative properties make it a valuable adjunct
in the management of a wide spectrum of liver conditions. As with all medications and
herbal-based therapies, its use should be guided by a healthcare professional, with
attention to individual risk factors, potential interactions, and appropriate monitoring.